Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease
- PMID: 17077181
- DOI: 10.1093/intimm/dxl110
Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease
Abstract
The MHC class I-like Fc receptor FcRn plays an essential role in extending the half-life (t(1/2)) of IgG antibodies and IgG-Fc-based therapeutics in the circulation. The goal of this study was to analyze the effect of human IgG1 (hIgG1) antibodies with enhanced in vitro binding to FcRn on their in vivo t(1/2) in mice expressing human FcRn (hFcRn). Mutants of the humanized monoclonal Herceptin antibody (Hu4D5-IgG1), directed against human epidermal growth factor receptor 2 (p185 (HER2)), show altered pH-dependent binding to hFcRn in vitro. Two engineered IgG1 mutants (N434A and T307A/E380A/N434A) showed a considerably extended t(1/2) in vivo compared with wild-type antibody in mice expressing an hFcRn transgene (Tg) but not in mice expressing the endogenous mouse FcRn. The efficiency of hFcRn-mediated protection was dependent on hFcRn Tg copy number. Moreover, when injected into FcRn-humanized mice at a concentration sufficient to partially saturate hFcRn, the engineered IgG1 mutants with an extended serum t(1/2) were most effective in reducing the t(1/2) of a tracer hIgG1 antibody. Finally, administration of mutant with high binding to hFcRn ameliorated arthritis induced by passive transfer with human pathogenic plasma. These results indicate that Fc regions modified for high binding affinity to hFcRn increases serum persistence of therapeutic antibodies, that the same approach can be exploited as an anti-autoimmune therapy to promote the clearance of endogenous pathogenic IgG and that FcRn-humanized mice are a promising surrogate for hIgG therapeutic development.
Similar articles
-
Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.J Immunol. 2010 Feb 15;184(4):1968-76. doi: 10.4049/jimmunol.0903296. Epub 2010 Jan 18. J Immunol. 2010. PMID: 20083659
-
Contribution of FcRn binding to intestinal uptake of IgG in suckling rat pups and human FcRn-transgenic mice.Am J Physiol Gastrointest Liver Physiol. 2013 Feb 1;304(3):G262-70. doi: 10.1152/ajpgi.00340.2012. Epub 2012 Dec 6. Am J Physiol Gastrointest Liver Physiol. 2013. PMID: 23220220
-
Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life.Mol Immunol. 2006 Mar;43(9):1462-73. doi: 10.1016/j.molimm.2005.07.032. Epub 2005 Sep 1. Mol Immunol. 2006. PMID: 16139891
-
Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.J Drug Target. 2014 May;22(4):269-78. doi: 10.3109/1061186X.2013.875030. Epub 2014 Jan 9. J Drug Target. 2014. PMID: 24404896 Review.
-
FcRn: the neonatal Fc receptor comes of age.Nat Rev Immunol. 2007 Sep;7(9):715-25. doi: 10.1038/nri2155. Epub 2007 Aug 17. Nat Rev Immunol. 2007. PMID: 17703228 Review.
Cited by
-
Impact of structural modifications of IgG antibodies on effector functions.Front Immunol. 2024 Jan 8;14:1304365. doi: 10.3389/fimmu.2023.1304365. eCollection 2023. Front Immunol. 2024. PMID: 38259472 Free PMC article. Review.
-
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics.Front Immunol. 2015 Jan 26;5:682. doi: 10.3389/fimmu.2014.00682. eCollection 2014. Front Immunol. 2015. PMID: 25674083 Free PMC article. Review.
-
The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy.Adv Drug Deliv Rev. 2015 Aug 30;91:109-24. doi: 10.1016/j.addr.2015.02.005. Epub 2015 Feb 19. Adv Drug Deliv Rev. 2015. PMID: 25703189 Free PMC article. Review.
-
Improving the efficacy of plant-made anti-HIV monoclonal antibodies for clinical use.Front Plant Sci. 2023 Feb 27;14:1126470. doi: 10.3389/fpls.2023.1126470. eCollection 2023. Front Plant Sci. 2023. PMID: 36923134 Free PMC article.
-
Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients.Antibodies (Basel). 2019 Jan 1;8(1):3. doi: 10.3390/antib8010003. Antibodies (Basel). 2019. PMID: 31544809 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous